ranibizumab (Lucentis, Genentech)

Study suggests ranibizumab superior for edema secondary to BRVOHead-to-head randomized controlled study found ranibizumab to show more favorable results to treating macular edema secondary to BRVO than a single dose of dexamethasone.
Subretinal fluid protective of vision, CATT study finds
Subretinal fluid protective of vision, CATT study findsSubretinal fluid was associated with better visual acuity, whereas greater thickness of the subretinal tissue complex was associated with worse visual acuity in the second year of the Comparison of Age-related Macular Degeneration Treatment Trials.
Managing pigment epithelial detachments with ranibizumab
Managing pigment epithelial detachments with ranibizumabLarge or small pigment epithelial detachments (PED) in neovascular age-related macular degeneration (AMD) can be managed effectively with ranibizumab PRN therapy with regular monitoring, said Rahul N. Khurana, MD.
FDA approves Eylea for all forms of macular edema after retinal vein occlusionThe U.S. Food and Drug Administration (FDA) recently approved Eylea (afilbercept, Regeneron) for all forms of macular edema after retinal vein occlusion, including branch retinal vein occlusion.
Ranibizumab approved by Health Canada, gains priority review for sBLA from FDAHealth Canada has approved Novartis Pharmaceuticals Canada’s ranibizumab (Lucentis) for the treatment of visual impairment due to choroidal neovascularization secondary to pathologic myopia (mCNV).
Delayed or immediate laser treatment for DME yield similar resultsAccording to research recently presented at the American Society of Retina Specialists annual meeting, focal or grid laser treatment that coincides with the initiation of intravitreal ranibizumab for the treatment of diabetic macular edema (DME) shows results no better than when laser treatment is deferred for 24 weeks or more.
AMD patients respond to aflibercept treatmentA study recently published in the British Journal of Ophthalmology found that patients with exudative age-related macular degeneration (AMD) who were incomplete responders to multiple ranibizumab injections (Lucentis, Genentech) saw improvements with aflibercept (Eylea, Regeneron) treatment.
Examining 1-year LUCAS Study results for AMD treatmentsThe 1-year results of the inject-and-extend Lucentis Compared to Avastin Study (Lucas) for exudative age-related macular degeneration (AMD) indicated that the two drugs have equivalent effectiveness, said Karina Berg, MD.